Omaxe Regulatory Approval

Omaxe Q2 FY27 Results: Net Loss of ₹25.6 Cr, Loss Narrows

Omaxe Ltd reported revenue from operations of ₹575.5 Cr (+79.4% YoY) and a net loss of ₹25.6 Cr for Q2 FY27.

Key figure

Net loss ₹25.6 Cr

Omaxe Merger & Restructuring Worth ₹0.01 Cr

Omaxe Limited approved incorporating a wholly owned subsidiary for real estate PPP projects. The subsidiary's subscription cost is Rs 1,00,000 for 100% equity.

Value

₹0.01 Cr

Omaxe Board Meeting Date

Omaxe Ltd scheduled a board meeting on October 27, 2026, to approve the standalone and consolidated financial results for the quarter ended September 30, 2026.

Omaxe Other Announcement

Omaxe Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended September 30, 2026.

Omaxe Product Launch

Omaxe Ltd announced the launch of a new commercial and service apartment project at 'Eternity - 2', targeting both domestic and international markets.

Omaxe Regulatory Approval

Omaxe Ltd received RERA registration for its 'Eternity - 2' commercial and service apartment project in Mathura. The approval facilitates sales, marketing, and project development.

From

Uttar Pradesh Real Estate Regulatory Authority

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.